What is the appropriate melatonin dosage for an adult with severe insomnia?

Melatonin Should Not Be Used for Severe Insomnia

The American Academy of Sleep Medicine explicitly recommends against using melatonin for the treatment of sleep onset or sleep maintenance insomnia in adults, even at the 2 mg dose studied in clinical trials. 1 This is a weak recommendation based on very low to low quality evidence showing that melatonin's benefits approximately equal its harms, with insufficient evidence demonstrating meaningful improvements in sleep outcomes. 2, 1

Why Melatonin Is Not Recommended

Lack of Efficacy for Insomnia

• The 2017 American Academy of Sleep Medicine guideline reviewed trials using 2 mg melatonin and found insufficient evidence for global and sleep outcomes, with only small effect sizes that did not translate to clinically meaningful improvements. 2
• The American College of Physicians similarly found insufficient evidence for melatonin's effectiveness in treating insomnia disorder. 2
• These guideline-level recommendations supersede individual research studies suggesting potential benefit, as guidelines synthesize the totality of evidence with rigorous methodology. 1

Quality of Evidence Issues

• The evidence supporting melatonin is rated as "very low to low quality" with benefits that "approximately equal harms," meaning there is no clear net benefit for patients with insomnia. 1
• The type and frequency of adverse effects did not differ significantly from placebo in trials, but the lack of efficacy makes the risk-benefit ratio unfavorable. 2

What Should Be Used Instead for Severe Insomnia

First-Line Pharmacologic Options

For adults with severe insomnia requiring pharmacologic treatment, the American Academy of Sleep Medicine suggests the following agents (all weak recommendations, but supported over melatonin):

For Sleep Onset Insomnia:

• Zaleplon 10 mg 1
• Triazolam 0.25 mg 1
• Ramelteon 8 mg (melatonin receptor agonist, not melatonin itself) 1

For Sleep Maintenance Insomnia:

• Suvorexant 10-20 mg (orexin receptor antagonist) 1
• Doxepin 3-6 mg 1

For Both Sleep Onset and Maintenance:

• Eszopiclone 2-3 mg 1
• Zolpidem 10 mg 1
• Temazepam 15 mg 1

Important Caveats About Benzodiazepines

• While temazepam and triazolam have evidence supporting their use, observational data links benzodiazepines (particularly those with half-lives exceeding 24 hours like diazepam and flurazepam) to increased dementia risk. 2
• The effect is greatest for higher-dose hypnotics and long-acting agents, so short-to-medium acting agents at appropriate doses are preferred when benzodiazepines are used. 2

Why Research Studies Conflict with Guidelines

Understanding the Discrepancy

• Recent research studies 3, 4, 5 suggest melatonin doses of 2-10 mg may be beneficial, with some meta-analyses showing optimal effects at 4 mg taken 3 hours before bedtime. 3
• However, these individual studies have not been incorporated into formal clinical practice guidelines, which represent the consensus of expert panels reviewing all available evidence with systematic methodology. 1
• The 2017 AASM guideline specifically reviewed melatonin trials and concluded the evidence was insufficient to recommend its use, despite some positive individual studies existing. 1

Special Populations Where Melatonin May Have a Role

• Prolonged-release melatonin 2 mg is indicated for insomnia in patients aged 55 years and older in some jurisdictions, based on evidence showing improvements in sleep quality and morning alertness in this specific age group. 6, 7
• Melatonin may have utility in circadian rhythm disorders (such as delayed sleep phase syndrome) rather than primary insomnia, though this is a different indication. 4
• In neuropsychiatric disorders, expert consensus suggests prolonged-release melatonin 2-10 mg may be appropriate, but this represents a specialized population. 4

Clinical Bottom Line

For an adult with severe primary insomnia, melatonin is not recommended based on current clinical practice guidelines. 1 Instead, consider FDA-approved hypnotics with demonstrated efficacy for insomnia, selecting the agent based on whether the patient has predominantly sleep onset difficulty, sleep maintenance difficulty, or both. 1 Non-pharmacologic approaches, particularly cognitive behavioral therapy for insomnia (CBT-I), should be prioritized when available, as current guidelines recommend this as first-line treatment. 8